Sigma Ligands For the Prevention or Treatment of Pain Induced by Chemotherapy
US-2016220575-A1 · Aug 4, 2016 · US
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9782483B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9782483-B2 |
| Application number | US-201113698718-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2011 |
| Priority date | May 21, 2010 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a patient afflicted with or at risk of emesis induced by chemotherapy or by radiotherapy comprising administering to the patient a selective sigma-1 receptor ligand in an amount effective to treat the patient, wherein the patient has cancer and is undergoing chemotherapy or radiotherapy and wherein the selective sigma-1 receptor ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt or solvate thereof. 2. The method of claim 1 , for the simultaneous treatment of chemotherapy or radiotherapy-induced emesis, and pain. 3. The method of claim 1 , wherein the selective sigma-1 receptor ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride. 4. A method for the treatment of cancer and simultaneous treatment of emesis induced by chemotherapy or radiotherapy in a patient, comprising administering to the patient a therapeutically effective amount of a combination of at least one selective sigma-1 receptor ligand and a least one chemotherapeutic drug simultaneously, separately or sequentially, wherein the selective sigma-1 receptor ligand is 4-{2[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt or solvate thereof. 5. The method of claim 4 , wherein the chemotherapeutic drug is selected from the group consisting of taxanes, vinca alkaloids and drugs derived from platinum. 6. The method of claim 4 , wherein the chemotherapeutic drug is selected from the group consisting of paclitaxel, oxaliplatin and vincristine. 7. The method of claim 4 , comprising administering to the patient 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt or solvate thereof and paclitaxel. 8. The method of claim 4 , comprising administering to the patient 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt or solvate thereof and oxaliplatin. 9. The method of claim 4 , comprising administering to the patient 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt or solvate thereof and vincristine. 10. The method of claim 4 , wherein the selective sigma-1 receptor ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride. 11. The method of claim 4 , comprising administering to the patient 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride and paclitaxel. 12. The method of claim 4 , comprising administering to the patient 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride and oxaliplatin. 13. The method of claim 4 , comprising administering to the patient 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride and vincristine.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
containing further heterocyclic ring systems · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9782483B2 cover?
- The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
- Who is the assignee on this patent?
- Vela Hernández José Miguel, Codony-Soler Xavier, Zamanillo-Castanedo Daniel, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).